Novel Therapeutic Strategies To Reduce The Burden Of Chronic Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$4,928,323.00
Summary
The broad aims of the Program are to develop novel strategies in the prevention and treatment of chronic heart failure. This will involve investigating new targets for pharmacological therapies, evaluating whether common co-morbid disease states such as diabetes alter the efficacy of these therapies and investigating the role of stem-cell therapy in this setting. The Program will also evaluate the contribution of non-heart failure drugs to the burden of heart failure, determine the impact of rur ....The broad aims of the Program are to develop novel strategies in the prevention and treatment of chronic heart failure. This will involve investigating new targets for pharmacological therapies, evaluating whether common co-morbid disease states such as diabetes alter the efficacy of these therapies and investigating the role of stem-cell therapy in this setting. The Program will also evaluate the contribution of non-heart failure drugs to the burden of heart failure, determine the impact of rurality on prescribing for this condition and explore systems of optimising delivery of best practice to the community. This research formalises the existing collaborative efforts of a team of investigators that span all aspects of research into the therapeutics of CHF from basic laboratory research to evaluation of patients in clinical trials and public health translational aspects of this condition. The Chief Investigators and Principal Investigators have an existing successful research collaboration which will be greatly expanded via Program.Read moreRead less
T Cell PKC Expression As A Novel Neonatal Predictor And Modulator Of Allergic Disease.
Funder
National Health and Medical Research Council
Funding Amount
$557,939.00
Summary
This application will further assess the role of a novel biological predictor of allergic disease, which appears more accurate than any previous marker (based on preliminary data). This is highly relevant to development of predictive tools that could be ultimately used in clinical practice. We will also assess this marker as a potential target for disease prevention, as our preliminary data also indicates that it can be modified by an early intervention aimed at preventing allergic disease.
Elucidating The Mechanisms By Which Bis(thiosemicarbazone)-copper Complexes Protect Neurons In Models Of Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$353,377.00
Summary
Dr Liddell is a neuroscientist investigating potential therapeutic agents for the treatment of diseases of affecting the brain such as Alzheimer’s disease and Parkinson’s disease. He is examining a class of metal-based compounds that are showing strong potential for disease treatment, and is investigating how these compounds work. The findings will be used to further develop and improve these therapeutic agents, and may help understand the underlying causes of these diseases.
Optimizing The Management Of Osteoarthritis Through Research And Innovation
Funder
National Health and Medical Research Council
Funding Amount
$2,889,164.00
Summary
I will test new treatments aimed at slowing disease progression and reducing pain in osteoarthritis (OA) by targeting specific disease pathways (metabolic factors and inflammation). I will undertake work examining the causes of hip OA where little is known. All required methodologies and resources to undertake this work are available and the trials underpinned by strong scientific rationale. This research program has high potential for translation and for reducing the burden and cost of OA.
Antibodies are the main line of defence the immune system utilises to target viruses and bacteria that invade our body. Raising the level of antibodies can therefore offer effective protection against disease. However, as antibodies cannot be taken orally (as a tablet) they have to be injected into the blood stream. We aim to overcome this limitation by generating antibodies that survive the passage through the stomach, allowing us to target conditions such as Crohn's disease.
More Effective Therapeutic Targeting Of High Risk Childhood Cancer: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$6,601,220.00
Summary
Cancer is the commonest cause of death from disease in Australian children. Childhood neuroblastoma is a particularly aggressive cancer, for which new treatment approaches are urgently needed. The team aims to discover better safer therapies for children with this cancer, conducting clinical trials using new drugs and novel drug combinations. We will also investigate novel ways of targeting neuroblastoma cells and identify therapeutic targets in neuroblastoma-initiating cells.
Integrated Exploration Of Novel Therapies For Depression
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
There is a clear need for new therapies for psychiatric illnesses, particularly depression. Current antidepressant therapy is useful but leaves many with a shortfall to functional recovery. My research program investigates new therapies for depression, in the context of the biological understanding of depression.